GET DAILY SIGNALSWhy Is Fortrea Holdings (FTRE) Stock Down -7% Today?
Key Takeaways
- FTRE shares fell roughly 7% in Thursday's session, trading near $21.52 versus a prior close of $23.14.
- The primary catalyst was the market's continued digestion of third-quarter results, including a $558 million reduction to reported backlog.
- Secondary pressure came from fourth-quarter guidance implying a sequential revenue slowdown and adjusted EBITDA below some analyst expectations.
- The move extended a two-day slide that began when the contract research organization reported results, even as it beat consensus revenue and EPS estimates.
- Traders are watching whether sell-side analysts revise estimates and whether the company can sustain its 1.12x book-to-bill momentum into 2027.
- For more detail, explore Price Targets, Earnings, and Forecast pages for FTRE.
- Interested in automated trading signals? Explore the Trending AI Robots page to see which strategies are performing best right now.
Opening Summary
Fortrea Holdings Inc. (FTRE), a global contract research organization (CRO) that provides clinical development and phase I–IV trial management services to pharmaceutical, biotechnology, and medical device companies, extended its post-earnings decline on Thursday. Shares fell about 7% to approximately $21.52, down from a prior closing price of $23.14. The decline confirmed bearish market reaction to the company's third-quarter 2026 report, with investors zeroing in on a sizable backlog adjustment and cautious fourth-quarter guidance even as headline results topped Wall Street estimates.
Backlog Reduction Weighs on Sentiment
The sharpest point of concern for investors was a $558 million cumulative adjustment to the company's backlog, which reduced the figure to roughly $7.3 billion at September 30. Management described the change as reflecting "inactive study" dynamics and "not-to-deliver" contract scopes across its FSO, MSP, and CPS portfolios. While executives stressed that the adjustment does not affect near- or medium-term revenue recognition, the magnitude of the revision raised questions about the quality of previously reported backlog and how much of the pipeline will ultimately convert to billable revenue.
Cautious Fourth-Quarter Outlook
Alongside the backlog news, the company signaled that fourth-quarter revenue is expected to slow sequentially, driven in part by fewer working days and a step-up in IT operating-expense investment. The implied fourth-quarter adjusted EBITDA guidance came in below some analysts' forecasts, tempering enthusiasm around the full-year guidance raise. Although Fortrea lifted the midpoints of its full-year 2026 revenue and adjusted EBITDA ranges while narrowing them, the near-term margin trajectory left traders unconvinced that profitability is accelerating fast enough.
Solid Quarter Overshadowed by Structural Concerns
The fundamental results were otherwise solid. Third-quarter revenue of $691.5 million beat consensus estimates of roughly $671 million, and adjusted earnings per share of $0.28 exceeded the $0.22 expected. Adjusted EBITDA rose 14% year over year to $58 million, and the book-to-bill ratio improved to 1.12x. However, revenue still declined 1.4% year over year, and the company's high customer concentration—its top 10 customers represented more than half of revenue—remained a persistent risk factor cited by analysts. These structural concerns, rather than the headline beat, dominated the market reaction.
Market Context and Trading Activity
Trading volume in FTRE was elevated relative to recent sessions, reflecting heavy turnover as investors repositioned following the earnings release and management's commentary. The stock's decline diverged from a relatively resilient broader healthcare and CRO complex, underscoring that the move was driven largely by company-specific factors rather than broad sector weakness. From a technical standpoint, the slide took shares below key short-term support levels and the prior session's range, reinforcing the bearish momentum that began when results were reported on October 29.
What Comes Next for FTRE
Investors will be watching for signs that the backlog adjustment is a one-time cleanup rather than a precursor to weaker bookings. Management's participation at the Jefferies Global Healthcare Conference in November and the company's fourth-quarter results will provide the next meaningful checkpoints on revenue conversion, margin expansion, and free cash flow. The recent completion of the Early Phase Services acquisition from Worldwide Clinical Trials adds clinical pharmacology capacity, but its contribution is not expected to turn EBITDA-positive until 2027. Risks include persistent revenue declines, customer concentration, and execution uncertainty as the company works to convert improving demand into sustainable, profitable growth.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots that are currently delivering the strongest performance under prevailing market conditions. While Tickeron offers hundreds of bots covering thousands of tickers, only the top performers are featured in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to evaluate. Explore the page to see which automated strategies are leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for FTRE shows an upward move is likely
FTRE's Aroon Indicator triggered a bullish signal on October 29, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 120 similar instances where the Aroon Indicator showed a similar pattern. In 103 of the 120 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on FTRE as a result. In 41 of 54 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +8.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTRE advanced for three days, in 155 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for FTRE moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 20 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
FTRE broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.197) is normal, around the industry mean (3.070). P/E Ratio (-27.873) is within average values for comparable stocks, (-1.257). Projected Growth (PEG Ratio) (0.344) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.491) among similar stocks. P/S Ratio (0.695) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. FTRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FTRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement